Derek DuBay

Derek DuBay

Auto-generated profile, based on publicly available information

Derek DuBay

Prisma Health Transplant Center, Medical University of South Carolina, Greenville, SC, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Annals of Surgery
Verified
Journal Article
Open access
DTDavid J. PharmD Taber
David J. PharmD Taber
JMJohn W. McGillicuddy
John W. McGillicuddy
CBCharles F. Bratton
Charles F. Bratton
VRVinayak S. Rohan
Vinayak S. Rohan
SNSatish Nadig
Satish Nadig
PBPrabhakar K. Baliga
Prabhakar K. Baliga
Objective: Determine the impact of cytolytic versus IL-2 receptor antibody (IL-2RA) induction on acute rejection, graft loss and death in African-American (AA) kidney transplant (KTX) recipients. Background: AAs are underrepresented in clinical trials in transplantation; thus, there is controversy regarding the optimal choice of perioperative antibody induction in KTX to improve outcomes. Methods: National cohort study using US transplant registry data from January 1, 2000 to December 31, 2009 in adult solitary AA KTX recipients, with at least 5 years of follow-up. Multivariable logistic and Cox regression were utilized to assess the outcomes of acute rejection, graft loss, and mortality, with interaction terms to assess effect modification. Results: Twenty-five thousand eighty-four adult AAs receiving solitary KTX were included, 16,927 (67.5%) received cytolytic induction and 8157 (32.5%) received IL-2RA induction. After adjustment for recipient sociodemographics, donor, and transplant characteristics, the use of cytolytic induction therapy reduced the risk of acute rejection by 32% (OR 0.68, 0.62–0.75), graft loss by 9% (HR 0.91, 0.86–0.97), and death by 12% (HR 0.88, 0.83–0.94). There were a number of significant effect modifiers, including public insurance, panel reactive antibody, delayed graft function, and steroid withdrawal; in these groups, cytolytic induction substantially improved clinical outcomes. Conclusions: These data demonstrate that cytolytic induction therapy, as compared with IL-2RA, reduces the risk of rejection, graft loss, and death in adult AA KTX recipients, particularly in those who are sensitized, receive public insurance, develop delayed graft function, or undergo steroid withdrawal.

9 July 2014 in Diagnostic and Therapeutic Endoscopy
Verified
Journal Article
Open access
PDF file
JRJayapal Ramesh
Jayapal Ramesh
NRNipun Reddy
Nipun Reddy
HKHwasoon Kim
Hwasoon Kim
KMKlaus Mönkemüller
Klaus Mönkemüller
SVShyam Varadarajulu
Shyam Varadarajulu
CWC. Mel Wilcox
C. Mel Wilcox
Background. Abnormal liver enzymes postorthotopic liver transplant (OLT) may indicate significant biliary pathology or organ rejection. There is very little known in the literature regarding the current role of diagnostic ERCP in this scenario. Aim. To review the utility of diagnostic ERCP in patients presenting with abnormal liver function tests in the setting of OLT. Methods. A retrospective review of diagnostic ERCPs in patients with OLT from 2002 to 2013 from a prospectively maintained, IRB approved database. Results. Of the 474 ERCPs performed in OLT patients, 210 (44.3%; 95% CI 39.8–48.8) were performed for abnormal liver function tests during the study period. Majority of patients were Caucasian (83.8%), male (62.4%) with median age of 55 years (IQR 48–62 years). Biliary cannulation was successful in 99.6% of cases and findings included stricture in 45 (21.4 %); biliary stones/sludge in 23 (11%); biliary dilation alone in 31 (14.8%); and normal in 91 (43.3%). Three (1.4%) patients developed mild, self-limiting pancreatitis; one patient (0.5%) developed cholangitis and two (1%) had postsphincterotomy bleeding. Multivariate analyses showed significant association between dilated ducts on imaging with a therapeutic outcome. Conclusion. Diagnostic ERCP in OLT patients presenting with liver function test abnormalities is safe and frequently therapeutic.

21 March 2025 in Kidney360
Verified
Journal Article
Open access
KSKarim Soliman
Karim Soliman
PAPrince Mohan Anand
Prince Mohan Anand
APAmy Perry
Amy Perry
Wisit CheungpasitpornWisit Cheungpasitporn
Wisit Cheungpasitporn
ADAhmed Daoud
Ahmed Daoud
DDDerek DuBay
Derek DuBay
An abstract is unavailable. This article is available as a PDF only.

25 March 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TRTaylor C. Remillard
Taylor C. Remillard
ACApryl C. Cronley
Apryl C. Cronley
NPNicole A. Pilch
Nicole A. Pilch
DDDerek A. Dubay
Derek A. Dubay
IWIra R. Willner
Ira R. Willner
RTRyan J. Tedford
Ryan J. Tedford

10 February 2026 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
JRJames R. Rodrigue
James R. Rodrigue
AFAaron Fleishman
Aaron Fleishman
JSJesse D. Schold
Jesse D. Schold
LMLila Medeiros
Lila Medeiros
KDKelli Collins Damron
Kelli Collins Damron
PBPrabhakar K. Baliga
Prabhakar K. Baliga